$-0.27 EPS Expected for TRACON Pharmaceuticals, Inc. (TCON)

October 13, 2018 - By Hugh Holland

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Logo

Analysts expect TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) to report $-0.27 EPS on November, 6.They anticipate $0.34 EPS change or 485.71 % from last quarter’s $0.07 EPS. After having $-0.33 EPS previously, TRACON Pharmaceuticals, Inc.’s analysts see -18.18 % EPS growth. The stock decreased 1.64% or $0.03 during the last trading session, reaching $1.8. About 61,861 shares traded. TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) has declined 34.33% since October 14, 2017 and is downtrending. It has underperformed by 49.95% the S&P500.

TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration , and fibrotic diseases. The company has market cap of $53.71 million. The Company’s lead product candidate is TRC105, an endoglin antibody, which is in Phase III clinical trials for angiosarcoma; randomized Phase II clinical trials for renal cell carcinoma; Phase II clinical trials for soft tissue sarcoma; Phase II clinical trials for gestational trophoblastic neoplasia; Phase I/II clinical trials for hepatocellular carcinoma; Phase I clinical trial for lung cancer; Phase I/II clinical trials for breast cancer; and Phase I/II clinical trials for wet AMD. It currently has negative earnings. The company's other product candidates comprise TRC102, a small molecule that is in Phase II clinical trials for mesothelioma, Phase II clinical trials for glioblastoma, Phase I clinical trial for solid tumors and lymphomas, as well as Phase I clinical trial for lung cancer; and TRC253, a small molecule high affinity competitive inhibitor of wild type androgen receptor (AR) and multiple AR mutant receptors that is in Phase I/II clinical trials for the treatment prostate cancer.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>